C. Charpentier

Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome

C. Charpentier, R. Landman, Cédric Laouenan et al. · Journal of Antimicrobial Chemotherapy · 2012 · 46 citations · Full text

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses

Sidonie Lambert-Niclot, C. Charpentier, Alexandre Storto et al. · Journal of Antimicrobial Chemotherapy · 2013 · 45 citations

Molecular Determinants of HIV-2 R5-X4 Tropism in the V3 Loop: Development of a New Genotypic Tool

Benoît Visseaux, Margarita Hurtado-Nédelec, C. Charpentier et al. · The Journal of Infectious Diseases · 2011 · 44 citations

HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies

Pierre Frange, Lambert Assoumou, Diane Descamps et al. · Journal of Antimicrobial Chemotherapy · 2015 · 44 citations · Full text

Phi Patients, Immunodeficiencies, First-line Strategies +17

Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens

Anne‐Geneviève Marcelin, C. Charpentier, Marc Wirden et al. · Journal of Antimicrobial Chemotherapy · 2012 · 27 citations · Full text